A Study of REC-1245 in Participants with Unresectable, Locally Advanced, or Metastatic Cancer

Description

This is a multi-center, open-label study to investigate the safety, tolerability, PK, PD, and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.

Conditions

Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a multi-center, open-label study to investigate the safety, tolerability, PK, PD, and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.

A Phase 1 / 2, Open-Label Study of REC-1245 in Participants with Unresectable, Locally Advanced, or Metastatic Cancer (DAHLIA)

A Study of REC-1245 in Participants with Unresectable, Locally Advanced, or Metastatic Cancer

Condition
Unresectable
Intervention / Treatment

-

Contacts and Locations

West Valley City

START Mountain Region, West Valley City, Utah, United States, 84119

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18 years or older Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
  • * Received treatment with another RBM39 degrader Clinically significant gastrointestinal (GI) or GI malabsorption

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Recursion Pharmaceuticals Inc.,

Study Record Dates

2028-10-30